Endometrial Cancer

The investigational ADC rinatabart sesutecan was given breakthrough therapy designation for use in patients with recurrent/progressive endometrial cancer.

In TP53 wild-type advanced or recurrent endometrial cancer, selinexor improved multiple time-to-event outcomes vs placebo.

Olanzapine plus an antiemetic shows potential in preventing RINV while reducing other adverse events such as depression, appetite loss, and insomnia.

Oncology nurses can enhance endometrial cancer recovery by fostering strong social support networks and improving communication with the patient.

Biocartis announced the launch of its real-time quantitative polymerase chain reaction assay to detect POLE and POLD1 mutations in endometrial cancer.

The safety and efficacy of dostarlimab plus chemotherapy in patients with advanced endometrial cancer were confirmed by results of a real-world study.

Palbociclib plus letrozole lengthened PFS vs placebo plus letrozole for patients with ER-positive advanced or recurrent endometrial cancer.

Patients treated with tyrosine kinase inhibitors received olanzapine to address adverse effects including nausea/vomiting, anorexia, insomnia, and weight loss.

The FDA has granted breakthrough device designation to the ACR-368 OncoSignature assay for use in endometrial cancer.

Sacituzumab tirumotecan had antitumor activity in pretreated advanced endometrial and ovarian cancer, data showed.

While adjuvant pembrolizumab and chemotherapy with or without radiation did not boost DFS in the overall high-risk endometrial cancer population, but showed a trend toward improved DFS in one patient subgroup.

Throughout August, the FDA approved drugs for the treatment of diseases including non-small cell lung cancer, cutaneous T-cell lymphoma, astrocytoma/oligodendroglioma, and endometrial cancer.

A dostarlimab-gxly combination was approved for advanced or recurrent endometrial cancer.

Adding dostarlimab to chemotherapy improved survival vs chemo alone in primary advanced or recurrent endometrial cancer.

Frontline durvalumab plus chemotherapy, followed by maintenance durvalumab with or without olaparib improved responses in stage III/IV or recurrent endometrial cancer.

Throughout June, the FDA approved drugs for the treatment of diseases including myelodysplastic syndrome, thyroid cancer, endometrial cancer, colorectal cancer, and follicular lymphoma.

The approval of this pembro-chemo combination for adults with primary advanced or recurrent endometrial carcinoma includes those with mismatch repair-proficient or -deficient disease.

The FDA approved durvalumab plus carboplatin and paclitaxel, followed by single-agent durvalumab for primary advanced or recurrent dMMR endometrial cancer.

Postmenopausal women who had undergone hysterectomy and received treatment with conjugated equine estrogen alone had an increased incidence of ovarian cancer and mortality rates.

Tiffany Bostwick, P.A., discussed the importance of communication and education around adverse effects for both oncology nurses and for patients with advanced endometrial cancer who are treated with immunotherapies.

Dostarlimab plus chemotherapy has been granted priority review from the FDA to expand its indication to all adult patients with primary advanced or recurrent endometrial cancer.

Pembrolizumab plus chemotherapy did not improve disease-free survival in patients with newly diagnosed, high-risk endometrial cancer, missing the primary end point of the phase 3 KEYNOTE-B21 study.

Over the last 5 years, 57% of drugs approved by the FDA for a cancer-related indication did not show a clinical benefit in confirmatory studies.

Criteria for progression-free and overall survival endpoints in patients with endometrial cancer with mismatch repair proficient disease were not met.

Discussions at a Community Case Forum event emphasized the importance of listening to patient concerns and a multidisciplinary approach when treating advanced endometrial cancer.